Plain-English translation of NCT06735391 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether , a new medication given by IV infusion, works better when combined with (a standard pill taken daily) compared to alone. The trial involves people with advanced non-small cell lung cancer that has specific EGFR gene mutations and has never been treated before. Researchers want to see if adding this medication to the standard treatment can help people live longer and control their cancer better.
is already a proven treatment for this type of lung cancer, but doctors want to know if combining it with this medication could improve results even further. This study will help determine whether the new combination is worth using for patients like you.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will randomly be assigned to one of two groups: one group receives by IV infusion every two weeks plus pills daily, and the other group receives pills alone. Treatment cycles last 4 weeks. You will have regular clinic visits for blood tests, imaging scans to measure your tumor, and check-ins about how you're feeling. The study will continue until your cancer progresses, you experience unacceptable side effects, or the study ends.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China